We applied a systematic pharmacogenetic approach to investigate the role of genetic variation in the gene encoding catechol O-methyltransferase (COMT) in individual variation in selective serotonin reuptake inhibitor (SSRI) response among depressed patients. In all, 23 single-nucleotide polymorphisms (SNPs) in COMT were genotyped using DNA from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (N ¼ 1914). One SNP, rs13306278, located in the distal promoter region of COMT, showed significant association with remission in White non-Hispanic (WNH) subjects (P ¼ 0.038). Electromobility shift assay for rs13306278 showed alternation in the ability of the variant sequence to bind nuclear proteins. A replication study was performed using samples from the Mayo Clinic Pharmacogenetics Research Network Citalopram/Escitalopram Pharmacogenomic study (N ¼ 422) that demonstrated a similar trend for association. Our findings suggest that novel genetic markers in the COMT distal promoter may influence SSRI response phenotypes.
Introduction
Major depressive disorder (MDD) is a common and serious illness with an estimated annual incidence in the United States of 16%. 1 Selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed class of antidepressants. 2 There are large individual variations in response to SSRIs, with reported remission rates of o50%. 2 We set out to test the hypothesis that common variation in the gene encoding catechol O-methyltransferase (COMT, EC 2.1.1.6), might influence response to SSRI therapy of MDD patients.
Biologically active monoamines, such as norepinephrine and serotonin, contribute to the regulation of mood and emotions. 3 Decades ago, Schildkraut proposed a 'chemical imbalance' theory which suggested that diminished levels of monoamine neurotransmitters might increase risk for depression. 4 COMT catalyzes the O-methylation of catecholamine neurotransmitters. 5 Therefore, variation in the activity of COMT could, in theory, modulate the efficacy of antidepressants that are designed to increase neurotransmitters at post-synaptic receptors. The COMT gene was cloned in 1989 6 and maps to chromosome 22q11, 7 a region of interest for several psychiatric disorders. 8 Two isoforms, a soluble cytoplasmic COMT and a membrane-bound COMT isoform are encoded by one gene with two promoters. A 'proximal promoter' for soluble cytoplasmic COMT is located in intron 2, whereas a distal promoter for membrane-bound COMT is found at the 5 0 -end of the gene. 9, 10 Membrane-bound COMT has an additional 50 hydrophobic amino acids at its N-terminus and is thought to be the predominant isoform expressed in the brain. 10 Genetic studies of COMT and its possible role in risk for diseases that range from depression to breast cancer date back over three decades. 11 Our laboratory first described common genetic polymorphisms that influence COMT activity over 30 years ago [12] [13] [14] and-more recently-a common COMT Val108/158Met (S/MB) polymorphism that is associated with the autosomal codominant regulation of level of COMT activity. 15 The Val108/158Met polymorphism has been studied extensively in psychiatric diseases, 16 as well as in diseases such as breast cancer. [17] [18] [19] However, those results have often been inconsistent. We recently conducted a study which suggested that functional polymorphisms in the distal promoter for membrane-bound COMT might be of greater importance for breast cancer risk than the Val158Met polymorphism. 20 Therefore, we set out to systematically investigate the possible role of COMT genetic variation in response to the SSRI therapy of MDD. In all, 23 single-nucleotide polymorphisms (SNPs) across the COMT gene (B28 kb) were selected based on gene resequencing data 21, 22 and public database information for use in genotyping 1914 DNA samples from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. [23] [24] [25] Only 33% of patients in the STAR*D study achieved complete 'remission' after citalopram therapy, that is, quick inventory of depressive symptomatology-clinician-rated (QIDS-C 16 ) p5, and only 47% 'responded', defined as a 50% reduction in QIDS-C 16 at the last visit. 25 We then preformed functional genomic studies and a replication study using 422 samples from the ongoing Mayo Clinic Pharmacogenetics Research Network (PGRN) Citalopram/Escitalopram Pharmacogenomic Study (Mayo PGRN SSRI Study). This systematic approach enabled us to identify a novel SNP in the COMT distal promoter that seems to be associated with remission during SSRI therapy.
Materials and methods

Study design and samples
An initial association analysis of 23 COMT SNPs was performed using samples from the STAR*D study. STAR*D patients were all treated initially with citalopram. In all, 1914 DNA samples from 4041 eligible STAR*D subjects were available for genotyping. The primary STAR*D outcome was 'remission', a QIDS-C 16 score p5 at the last clinic visit. 26 The Mayo PGRN SSRI Study is an ongoing clinical trial designed to parallel the STAR*D design. Specifically, MDD patients from the Mayo Clinic practice are treated with either citalopram or escitalopram and must have a 17-item Hamilton Depression Rating Scale (HRD-D17) score of 414 to enter the study. Exclusion criteria are also similar to those used in STAR*D. Patients are seen at entry, week 4 and week 8 for clinical evaluation and to obtain blood samples. Over 600 patients have been enrolled to date and 422 DNA samples were available for genotyping when this study was performed. The Mayo PGRN SSRI Study was reviewed and approved by the Mayo Clinic Institutional Review Board, and all participants provided written informed consent.
SNP selection and genotyping
In all, 23 SNPs were selected from previous resequencing data 21, 22 using haplotype tagging, 27 or linkage disequilibrium tagging approaches 28 as well as on the basis of previous reports from clinical association studies. 29, 30 Genotyping for the STAR*D discovery study was performed using the Illumina Veracode (BeadXpress) platform (Illumina, San Diego, CA, USA) and Taqman (Applied Biosystems, Foster City, CA, USA) genotyping was used for the Mayo validation study.
Single SNP associations with remission
Samples with o90% call rates, ambiguous calls or data for patients with insufficient baseline depressive symptoms (QIDS-C 16 score o10) were removed from the analysis. Tests for Hardy-Weinberg Equilibrium were performed for the entire sample, and within self-reported ethnic groups. For binary phenotypes, that is, remitter versus non-remitter, tests of association between remission and each SNP were performed in each ethnic subgroup after excluding 33 subjects who failed to have sufficient depressive symptoms at baseline (QIDS-C 16 score of o10). A P-value was calculated for each SNP on the basis of a logistic regression model, assuming a log-additive allele effect on the odds of remission. For consistency with earlier STAR*D publications, the analysis was repeated for a subset of patients that included patients who remained in the study for at least 6 weeks and were not 'non-compliant'. 26 Remission is strongly associated with medication 'tolerance'. 31 Therefore, we also performed univariate tests of association between remission and each SNP in ethnic subgroups, adjusted for medication tolerance. All patients who continued citalopram therapy at the end of STAR*D phase 1 treatment were considered tolerant, while patients who refused to continue citalopram or left because of side effects were considered intolerant. Genetic effects were adjusted for tolerance by including tolerance as a covariate in the model. We also performed an analysis with an adjustment for tolerance, days in study and medication dose.
As remission is the goal of treatment, most STAR*D analyses have focused on this outcome. 23, 24, 26 However, quantitative change in QIDS-C 16 scores might provide additional information with regard to drug response, and analyses of QIDS-C 16 values might provide enhanced power. Therefore, we determined associations between COMT SNPs and QIDS-C 16 scores at the end of the treatment using linear regression. The final QIDS-C 16 score or the % change in QIDS-C 16 were also considered as outcomes, with baseline QIDS-C 16 as a covariate.
Electromobility shift (EMS) assays
Since the SNP that was associated with SSRI response in our discovery study was located in the distal promoter region of COMT, rather than in the open reading frame, we set out to perform EMS assays to determine the possible effect of this SNP on transcription regulation by determining whether nuclear protein(s) might bind to the SNP locus and also whether alternation in the SNP nucleotide at this locus could alter its ability to bind nuclear protein(s). Previous reports have demonstrated that, in the brain, COMT is expressed mainly in glial cells. 32 Therefore, the EMS assays were performed using human U-87 MG glioma cell nuclear extract (Active Motif, Carlsbad, CA, USA). Specifically, biotin-labeled and unlabeled oligonucleotides were synthesized by Integrated DNA technologies (Coralville, IA, USA). Oligonucleotide sequences for the COMT 5 0 -FR(-485) SNP were wild-type: 5 0 -gccccagtttcCccacctgggaa-3 0 and variant:
Details of the EMS assays have been described elsewhere. 20 Bioinformatic analyses rVISTA, a transcription factor website database that includes comparative sequence analysis web-based 'tools', indicated that the 5 0 -FR(-485) SNP was located within a 2711-bp region between chromosome 22 positions 18308090 to 18310800 that shared 92.6% identity with the sequence of the rhesus macaque and contained a cluster of predicted transcription factor binding sites. 33, 34 In silico analysis using AliBaba 2.1 35 predicted that the region surrounding COMT 5 0 -FR(-485) might contain an Sp1-binding motif and that a C to T alteration at this locus, although remaining a partial Sp1 site, would result in a new transcription factor binding motif, C/EBPa.
Results
STAR*D genotyping
In all, 23 SNPs located across the entire COMT gene (B28 kb) were genotyped in DNA samples from the STAR*D study. The gene structure of COMT is depicted graphically in Figure 1a , with locations and allele frequencies for the SNPs genotyped in STAR*D samples as well as those identified during our resequencing of European American DNA samples. Of the 1903 samples from STAR*D subjects that were genotyped successfully, 33 had inadequate phenotypic data, so 1870 samples were analyzed, including 1232 WNH, 287 Black, 238 White Hispanic (WH) and 113 of 'other' self-reported ethnicity. There was some evidence of departure from Hardy-Weinberg Equilibrium for rs165774 in WNH subjects (P-value ¼ 0.0085), and rs165722 and rs3810595 in Black subjects (P-values ¼ 0.0057 and 0.0029, respectively).
Association of remission with COMT SNPs
Remission status was determined on the basis of QIDS-C 16 at the last clinic visit. 25, 26 Of the STAR*D samples genotyped, there were 541 WNH remitters (44% of the WNH subjects), 93 Black remitters (32% of Black subjects) and 78 WH remitters (33% of the WH subjects). Associations of COMT SNPs with remission status for the STAR*D patients are summarized in Table 1. One SNP, 5 0 -FR(-485)C/T (rs13306278) located in the COMT distal promoter, seemed to be associated with lack of remission (unadjusted P-value ¼ 0.038) in WNH subjects, with an allele-specific odds ratio (OR) of 0.78 (95% confidence interval, 0.62-0.99). A similar trend of association was also present for this same SNP in the WH subjects, with an OR of 0.56 (95% confidence interval, 0.26-1.18). However, this SNP had a very low minor allele frequency (2-3%) in the Black subjects and was not associated with remission in that ethnic group. In addition, a SNP in the 3 0 -FR of the gene, 3 0 -FR(23) (rs9332381), showed a significant association (P-value ¼ 0.006) with remission in WNH subjects, with an OR of 1.71 (95% confidence interval, 1.16-2.51), but was not significant in the other two ethnic groups, especially Black patients in whom the minor allele frequency (MAF) was an order of magnitude higher than in WNH subjects. These two SNPs displayed similar association trends when the analysis was performed within a subset that included only patients who were 'compliant' and remained in the study for at least 6 weeks (P-values for rs13306278 and rs9332381 of 0.015 and 0.028, respectively; Supplementary Table 1 ). When the effects of 'tolerance', days in study, and final drug dose were taken into account, the association between rs13306278 and remission was even more significant (P-value ¼ 0.003; Supplementary Table 2) . However, rs9332381 failed to show an association for this analysis.
Although the associations that we observed were not significant after correcting for multiple comparisons, this initial discovery study had identified 'SNP signals' that could be pursued. Therefore, we conducted functional genomic experiments for rs13306278 and, subsequently, a validation study using additional clinical samples. We also performed haplotype analyses, but those results showed that rs13306278 was responsible for most of the haplotype effects. Those analyses are described in the Supplementary Materials. Finally, it should be noted that these analyses did not indicate that the functionally significant COMT Val108/ 158Met polymorphism was a factor in SSRI response.
Association of a quantitative trait with COMT SNPs
Quantitative trait analysis performed using final QIDS-C 16 score as an 'outcome' indicated that rs9332381 was significantly associated with this phenotype (P-value p0.001) in WNH subjects, but not in the Black or WH subjects. In addition, rs4633 in COMT exon 3 showed some evidence of association, but only in Black subjects (P-value ¼ 0.013). The rs13306278 SNP was not significantly associated with this measure of response to SSRI therapy (Supplementary  Table 3 ). However, it was associated with baseline quantitative QIDS score in the WNH subjects, with the minor allele being associated with higher baseline QIDS score, representing more severe depression at study entry (P ¼ 0.013).
Functional genomic studies EMS assay was performed for the rs13306278 SNP using human glioma U-87 MG cell nuclear extract. Figure 2a shows that glioma cell nuclear protein(s) bound to oligonucleotides containing the wild-type nucleotide at the 5 0 -FR(-485) locus, and that a C to T change at this nucleotide resulted in a striking reduction in binding. rVISTA predicted that this region of the gene included many possible transcription factor binding motifs. Alibaba 2.1 suggested that this area might be an Sp1-binding site in the wild-type sequence that would be partially replaced by a C/EBPa (CCAAT/enhancer-binding protein) binding motif in the variant sequence (Figure 2b ). C/EBPa regulates gene expression in a variety of tissues 36 and its expression is detectable in brain. 37 This evidence of biological plausibility stimulated us to attempt to validate our STAR*D observations using samples from an independent SSRI study.
Replication study
The Mayo PGRN SSRI Study is an ongoing SSRI pharmacogenomic clinical trial that was designed to parallel STAR*D. A total of 605 patients have been enrolled thus far. The overall remission rate determined by the 8-week QIDS-C 16 score was 48.4%, similar to the 44% remission rate observed among WNH subjects in the STAR*D study. 26 On the basis of our observations with DNA from the STAR*D study and our functional genomic experiments, we genotyped only a single SNP, rs1330628, for validation. The call rate for this TaqMan assay was over 99%. Of the 422 DNA samples genotyped for the Mayo study, 391 were from WNH subjects. In all, 356 subjects had remission status determined on the basis of 8-or 4-week QIDS-C 16 scores, On the left is the COMT LD structure in the STAR*D WNH population, and on the right is COMT LD structure derived from polymorphisms identified during our COMT resequencing studies performed with 60 EA DNA samples. 21, 22 Polymorphisms with minor allele frequencies of greater than 5% were included in the linkage disequilibrium analyses. S, soluble. The numbering scheme for the SNPs was adapted from our previous study. Specifically, numbering of nucleotides in the coding region began at the 'A' in the 'ATG' for membrane-bound COMT, with nucleotides 3 0 to that position assigned positive numbers. Nucleotides located within the two upstream non-coding exons, and the 5 0 -FR were assigned negative numbers, with the final nucleotide of exon 2 designed as 'À1'.
Nucleotides located within introns were numbered on the basis of distance form the nearest splice site, using positive and negative numbers for distance to 5 0 -and 3
0
-splice sites, respectively. The numbering scheme for amino acids is based on their distance from the membrane-bound COMT translation start codon. Note: the 5 0 -FR(-485) SNP that was pursued in our replication study and the heavily studied Val108/158Met SNP (rs4680) are 'boxed'. *Trend test P-value assuming a log-additive allele effect, not adjusted for multiple comparisons.
a SNPs that we recently reported to be important for risk for breast cancer. 20 including 160 remitters and 196 non-remitters. Statistical analysis was performed using remission status at the last visit (either the 8-week QIDS-C 16 score or the 4-week QIDS-C 16 score) as the outcome. Assuming a log-additive allele effect, the OR for association between the 5 0 -FR(-485) locus and remission status was 0.68 (95% confidence interval, 0.42-1.09; Table 2 ). Although these results were not statistically significant (P-value ¼ 0.11), which is not surprising given the smaller sample size as compared with STAR*D, the trend of association was similar to what we observed for the STAR*D WNH subjects. In addition, MAFs for rs1330628 in the Mayo PGRN SSRI WNH subjects were consistent with those that we had observed in the STAR*D study (15% in non-remitters and 12% in remitters, Table 2 ). In addition, as in the STAR*D WNH sample, the minor allele of this SNP in the replication samples was once again associated with higher baseline QIDS scores (P ¼ 0.004).
Discussion
SSRIs are the most widely prescribed class of antidepressants. 2 However, only two-thirds of MDD patients respond to SSRI therapy and even fewer are able to achieve remission. 38 Therefore, many candidate pharmacogenetic studies have been performed with SSRIs with the goal of identifying genetic markers that might help to predict variation in response to treatment. 31, [39] [40] [41] [42] COMT catalyzes the metabolism of catecholamine neurotransmitters that are thought to have a role in mood regulation, based on the 'chemical imbalance' theory for depression. 4 The fact that COMT maps to the long arm of chromosome 22, a region of interest for several psychiatric phenotypes, has also served to stimulate studies that focus on the possible role of COMT genetic polymorphisms in neuropsychiatric diseases and response to the treatment of those disorders. 16 The common functional COMT Val108/ 158Met polymorphism that is associated with altered enzyme activity and thermal stability during in vitro assays is responsible, in large part, for a tri-modal distribution of COMT enzyme activity in red blood cells, lymphocytes and liver. 11, 15, 21, 22 Therefore, most studies designed to examine associations between COMT polymorphisms and clinical phenotypes have focused on this SNP. However, the results of those studies have been inconsistent. Three of those studies reported a similar trend of association with antidepressant treatment outcome, that is, that carriers of the Val allele might have better antidepressant treatment outcomes than patients homozygous for Met108/158. [43] [44] [45] As the Val allele is associated with elevated COMT activity, this result seemed to indicate that decreased catecholamine neurotransmitters might enhance drug response-in contrast to our understanding of the role of monoamines in the pathophysiology of depression. Because most of those studies were performed with relatively small numbers of patients and several reported associations that were difficult to explain mechanistically, it has been difficult to draw conclusions about a possible role for COMT in SSRI response. Therefore, we set out to systematically examine the possible role of COMT sequence variation in individual variation in response to SSRI therapy.
As an initial 'discovery' effort, a total of 23 SNPs across the entire length of COMT were genotyped in STAR*D subjects. The STAR*D study was not designed to evaluate the efficacy of SSRIs, but-like a large number of observational pharmacogenomic studies-factors that might influence SSRI outcome. The same is true of the Mayo-PGRN SSRI study, which was specifically designed to address pharmacogenomic influences from both pharmacokinetic and pharmacodynamic factors on SSRI outcome. SNP rs13306278 in the distal promoter of COMT was associated with a decreased rate of remission, was validated functionally and a similar trend was observed in an independent SSRI clinical trial. We also observed an association with a SNP at 3 0 -FR(23). However, that association was only observed in WNHs, an ethnic group in which this SNP is present with a low MAF (3-5%). As a result, we were unable to pursue that SNP further. The heavily studied Val108/158Met polymorphism did not seem to be associated with remission in our study. Haplotype analysis (see Supplementary Material) provided further evidence that the COMT 5 0 -FR and intron 1, the region that contains the distal promoter, was of importance for SSRI response. However, that association also seemed to be driven, largely, by the rs13306278 SNP. Furthermore, DNA sequence conservation and transcription factor binding site analyses suggested that the area from 5 0 -FR(-1422) to intron 1(1380) of the COMT gene contained a cluster of transcription factor binding motifs and was highly conserved between rhesus macaque and humans, suggesting a possible functional role for this region. In a recently published genome-wide association study performed with STAR*D samples, 46 no association was observed between rs13306278 and remission. That is not surprising since the STAR*D genome-wide association study was performed with Affymetrix platforms that do not contain rs1330278. Therefore, the approach used in this study of applying in-depth gene resequencing data to perform an association study has demonstrated its utility in terms of the discovery of novel variants in candidate genes.
MAFs for rs13306278 in WNH subjects in the STAR*D population were 0.12 for remitters and 0.15 for nonremitters, respectively, resulting in an OR of 0.78 and P ¼ 0.038 for a log-additive effect. Assuming that this is a 'true' effect size, and with similar MAFs in remitters and non-remitters among the patients in the Mayo PGRN samples, we were not surprised that we were unable to observe a significant association in the replication population of 422 subjects. However, the observed association of SNP rs13306278 with remission in the Mayo study was consistent with our observations for STAR*D, both with regard to direction and effect size.
Both the STAR*D and the PGRN SSRI studies uses a singlearm design, which is commonly and effectively used in many pharmacogenetic studies. However, with these single arm studies, it is not possible to determine whether a particular SNP influences SSRI response specifically, or is related to depression treatment outcomes or disease prognosis more generally. Nevertheless, from our results we can conclude that, in two large studies, the minor allele at SNP rs13306278 was associated with lower rates of remission of depression after SSRI therapy. Our results also indicated that this allele was associated with higher baseline QIDS scores, indicating greater severity of depression at study entry. These results suggest that the lower rates of remission associated with this SNP may be, at least partially, a reflection of more severe depression. Further studies evaluating the association of this SNP with depression severity and prognosis following other forms of treatment would clearly be of interest.
In summary, our studies have identified a distal promoter SNP in COMT that may play a role in individual variation in response to SSRI treatment. These findings indicate that polymorphisms in the distal promoter region of COMT might influence response to SSRI therapy, and as a result, they have provided novel candidate polymorphisms for studies of both antidepressant pharmacogenetics and, possibly, depression risk.
